---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-053897"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:39:36.535276+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytek Q4 revenue $48.3M (+24% YoY); guides FY2023 $225-235M (+37-43%)

## Summary
- Full-year 2022 revenue $164.0M, up 28% YoY (34% constant currency); net income $2.5M.
- Q4 net income $3.7M vs loss $1.2M in Q4 2021; adjusted EBITDA $6.6M.
- 2023 revenue guidance $225-235M, including ~$20M from Luminex acquisition closed Feb 28.
- Acquired Luminex's Flow Cytometry and Imaging business; partnership with Bio-Rad.
- Cash and short-term investments $341.1M; 560 instrument placements in 2022.

## SEC filing metadata
- accession: 0001193125-23-053897
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312523053897/0001193125-23-053897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312523053897/d462230d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-053897
- JSON: https://secwatch.observer/filing/0001193125-23-053897.json
- Plain text: https://secwatch.observer/filing/0001193125-23-053897.txt

## Key facts
- Earnings Releases
  Cytek Biosciences, Inc. reported full year 2023 results: revenue $225 million to $235 million. Guidance initiated.
  - Period: full year 2023
  - Revenue: $225 million to $235 million
  - Guidance: initiated
  - Result: guidance update
  source text: Cytek Biosciences expects full year 2023 revenue in the range of $225 million to $235 million, representing growth of 37% to 43% over full year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312523053897/0001193125-23-053897-index.htm
- Earnings Releases
  Cytek Biosciences, Inc. reported the year ended December 31, 2022 results: revenue $164.0 million, net income $2.5 million.
  - Period: the year ended December 31, 2022
  - Revenue: $164.0 million
  - Net income: $2.5 million
  - Result: reported results
  source text: Total revenue for the year ended December 31, 2022 was $164.0 million, a 28% increase over the year ended December 31, 2021. On a constant currency basis, total revenue for the full year 2022 was $171.8 million, a 34% increase over the full year 2021. Gross profit was $101.0 million for the year ended December 31, 2022, an increase of 28% compared to a gross profit of $79.1 million in the year ended December 31, 2021. Gross profit margin was 62% in the year ended December 31, 2022 compared to 62% in the year ended December 31, 2021. Adjusted gross profit margin in the year ended December 31, 2022 was 63% compared to 63% in the year ended December 31, 2021, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles. Operating expenses were $102.8 million for the year ended December 31, 2022, a 47% increase from $70.0 million in the year ended December 31, 2021. The increase was primarily due to expenses to support continued growth of the bus
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312523053897/0001193125-23-053897-index.htm
- Earnings Releases
  Cytek Biosciences, Inc. reported the fourth quarter of 2022 results: revenue $48.3 million, net income $3.7 million.
  - Period: the fourth quarter of 2022
  - Revenue: $48.3 million
  - Net income: $3.7 million
  - Result: reported results
  source text: Total revenue for the fourth quarter of 2022 was $48.3 million, a 24% increase over the fourth quarter of 2021, with continued demand across the full portfolio of Cytek’s offerings. On a constant currency basis, total revenue for the fourth quarter of 2022 was $51.2 million, a 32% increase over the fourth quarter of 2021. Gross profit was $29.4 million for the fourth quarter of 2022, an increase of 24% compared to a gross profit of $23.6 million in the fourth quarter of 2021. Gross profit margin was 61% in the fourth quarter of 2022 compared to 61% in the fourth quarter of 2021. Adjusted gross profit margin in the fourth quarter of 2022 was 62% compared to 63% in the fourth quarter of 2021, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles. Operating expenses were $29.3 million for the fourth quarter of 2022, a 31% increase from $22.3 million in the fourth quarter of 2021. The increase was primarily due to expenses to support conti
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312523053897/0001193125-23-053897-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.